Dr. Bill Poland Will Discuss Best Practices in HCV and HIV Drug-Disease Modeling and Simulation to Support Clinical Drug Development Decision
MOUNTAIN VIEW, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Bill Poland, Ph.D., vice president and lead scientist, Strategic Consulting Services, will speak to members of the pharmaceutical and biotechnology industries via web conference on HCV/HIV drug-disease modeling on Thursday, February 28, 2008, at 1:00 p.m. Eastern Standard Time (10:00 a.m. PST).
Dr. Poland's presentation, entitled "Portable Concepts for HCV and HIV Drug-Disease Modeling and Simulation" will discuss the use and strategic value of quantitative modeling and simulation to design, predict and improve clinical trial outcomes for HCV and HIV drugs. Applied case examples will illustrate that despite important differences between HCV and HIV, such as the potential to cure HCV and faster HCV dynamics, HCV trial outcomes, like those for HIV, can be predicted and improved by model-informed design. More information about this event is available at http://www.pharsight.com/events/events_home.php.
"HCV and HIV present special therapeutic challenges to drug development
teams, including the emergence of resistance, complex pharmacokinetics, and
patient compliance," said Shawn O'Connor, president, CEO and chairman of
Pharsight. "To support planning and quantitative decision-making for
antiviral development, it is important to leve
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved